Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. - Wikidata - wikimedia - TriplyDB

Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies.

Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies.

http://www.wikidata.org/entity/Q33893627

about

High dose versus standard dose proton pump inhibitor for short term management of erosive reflux oesophagitis Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.Perils and pitfalls of long-term effects of proton pump inhibitors.A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors.Age and gender differences in the prevalence and patterns of multimorbidity in the older population.Risk of fracture and pneumonia from acid suppressive drugs.Use of selective serotonin reuptake inhibitors and risk of fracture: a systematic review and meta-analysis.Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis.Is gastrectomy-induced high turnover of bone with hyperosteoidosis and increase of mineralization a typical osteomalacia?Prescribing efficiency of proton pump inhibitors in China: influence and future directions Acid-suppressive medications and risk of fracture: an updated meta-analysis.Adverse Event Reporting for Proton Pump Inhibitor Therapy: An Overview of Systematic Reviews.The Indications, Applications, and Risks of Proton Pump Inhibitors DUEXIS(®) (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug.The role of one-year endoscopic follow-up for the esophageal remnant and gastric conduit after esophagectomy with gastric reconstruction for esophageal squamous cell carcinoma Potential harms of proton pump inhibitor therapy: rare adverse effects of commonly used drugs Influence of proton pump inhibitors and histamine H2 receptor antagonists on serum phosphorus level control by calcium carbonate in patients undergoing hemodialysis: a retrospective medical chart review.Efficacy and Safety of Modified Banxia Xiexin Decoction (Pinellia Decoction for Draining the Heart) for Gastroesophageal Reflux Disease in Adults: A Systematic Review and Meta-Analysis.The risks of PPI therapy.Fracture risk and bone mineral density reduction associated with proton pump inhibitors.A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada.Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease.Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease.Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence.Initiatives in South Africa to enhance the prescribing of generic proton pump inhibitors: findings and implications.Examining the potential relationship between proton pump inhibitor use and the risk of bone fracture.Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis.Balancing the risks and benefits of proton pump inhibitors.Diclofenac sodium topical solution 1.5% w/w with dimethyl sulfoxide compared with placebo for the treatment of osteoarthritis: pooled safety results.Incidence and predictors of osteoporotic fractures in patients with Barrett's oesophagus: a population-based nested case-control study.In This Issue: Personalizing Health Care.Medication use before and after hip fracture: a population-based cohort and case-control study.Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults.Hydroethanolic extract of Baccharis trimera promotes gastroprotection and healing of acute and chronic gastric ulcers induced by ethanol and acetic acid.Proton-pump inhibitors and risk of fractures: an update meta-analysis.Quantifying Candidacy for Deprescribing of Proton Pump Inhibitors among Long-Term Care Residents

P2860

Q24202482-0316126F-6003-4F76-AC8B-865E70A6CA85 Q26864640-25F0B2EA-BCFF-4200-8E63-978473DF910F Q30415171-971BB8A0-A373-43E1-AAB8-70C12D29D404 Q33409626-DED92F45-14F0-4429-9EBA-5E89766BA884 Q33441225-F85D2B6A-7C31-474F-8C72-3A142BD91584 Q33804321-28F1B964-899C-4B50-BD59-04FFECE01FC6 Q34092977-D912342A-541A-4E6A-85E3-9E8F581A6433 Q34132829-9FAC1BAD-96C3-4678-A3C5-9D680ED8C6F2 Q34510524-6F203E86-2FF2-4487-9CFF-030C2D9A4E80 Q34775881-4D785904-F781-4EC9-BF59-51A64FDFA1EB Q35021173-F5550BE5-473F-4D28-8BB0-744A224515FF Q35959430-937B0D9E-1219-4D09-9E25-045B39F0A8D1 Q36020285-434E98EF-A7D8-4EB5-B7F8-BAA995143E2A Q36091187-CBC0D638-6623-45EE-B767-F382DE2D18AE Q36280849-1C54EAEB-5266-4B6C-A598-74D13EDB33CC Q36620349-5F26BB72-CADF-4CF2-85BE-3D48E9CC1CD7 Q36993852-43D7894F-9A8B-4E40-8FFD-CC98BBD02FED Q37431931-4B4E69DB-BDE4-463F-85DB-621FB9BC5389 Q37681015-7AE5B5F7-A0E9-481C-979A-B3500445CDA1 Q37983706-1203D993-56C5-4965-9A47-74F57EEF05DA Q37990890-1539892F-E8C3-41D2-8365-F6AB2A662232 Q38073139-517C1526-16F6-4A15-A01F-38A73D69102A Q38096342-6688B783-B118-45BB-9BAA-8E813518BE77 Q38098574-35EFAF95-7A42-4B39-9EA2-6601EBEB29CF Q38229080-7457AD27-B4BA-4F00-BDA9-9C66C288C7BF Q38865456-40915BF7-F192-4FC5-ACFA-FC238EFDB6A2 Q40071378-21F0637C-1A22-4269-94F0-1A8AD8253179 Q41136557-403AC3D5-B644-423A-B52B-13C96A97AB74 Q41157508-0FFA28BF-6219-4F17-8F1C-4410FC6D1ABC Q42695192-AE39EADE-B2F4-4DC1-9D09-ED898A42ABA3 Q42729627-A2A57E82-E3F1-4098-ABFD-4375496D8AB6 Q46601875-16F69A29-2D18-42DE-9778-064B3782986E Q47619259-D50B8A5D-3C48-4681-A3DA-291C3A29677D Q50300626-B9D95E59-EEBA-4CAC-AEC5-5D8B646E390B Q51140318-6B039028-2EC7-416D-8CAD-A857B1DEAF5F Q52574981-5F0EF49F-27CD-41A5-8A9C-6927AF2D9B0D Q53083021-DEC8C68D-943E-42C2-89AB-24F0ED54C4B1 Q55059359-E223998B-BB69-4E35-B55F-A91E24B696CA Q58557250-20187C22-36FE-47EC-91E2-7F53DFD6A367

P2860

Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies.

http://www.wikidata.org/entity/Q33893627

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Use of acid-suppressive drugs ...... ysis of observational studies.

@ast

Use of acid-suppressive drugs ...... ysis of observational studies.

@en

type

label

Use of acid-suppressive drugs ...... ysis of observational studies.

@ast

Use of acid-suppressive drugs ...... ysis of observational studies.

@en

prefLabel

Use of acid-suppressive drugs ...... ysis of observational studies.

@ast

Use of acid-suppressive drugs ...... ysis of observational studies.

@en

P1433

Q33893627-F0315A02-2069-45DD-847A-6D53006DC00D

P1476

Q33893627-676B9B78-89FA-416D-95CC-58D4286CECEA

P2093

Q33893627-6212D196-B35F-46F1-8475-6372D164FEA5

Q33893627-623AFD23-369A-406B-BC32-9ADA2888C58E

Q33893627-B00E7830-3C4B-4C2A-9022-62E70F7B268F

Q33893627-C3B54E54-43DD-461B-AD55-0937C59DB92D

P2860

Q33893627-022D08B8-4DC4-4A4B-9E80-032BB87B0EEE

Q33893627-080795B6-C586-45D5-B22C-3107FD2C8288

Q33893627-0DAE7422-643C-4A67-A287-B90A899830BE

Q33893627-11434107-46CD-49B3-95A3-C4F2852BBF1F

Q33893627-1721BD7D-048C-41EC-89B6-D158163FCE3E

Q33893627-2E1472A0-4889-4204-8EE9-5ED666B8EF33

Q33893627-3239F452-A4D5-44BD-9873-9E97BD159EFC

Q33893627-33585532-239B-4FC0-A6D5-72A94AF38990

Q33893627-33A869BB-26C8-4BC9-BFD3-5153BF9386CD

Q33893627-3C067BE7-B305-47F4-8E2A-9957F8BC29FD

P304

Q33893627-BD868F48-D14A-4012-B8E1-3888C1B1A72D

P31

Q33893627-2AF7183A-F53B-489A-8B68-CEA400F317B8

Q33893627-b6ea1978-109f-4240-995b-1c2295a3a1ce

P356

Q33893627-DC2EEA5C-73D0-4E74-845D-BEB9DA17EDD9

P407

Q33893627-AE1A2B68-E47D-4C7F-B980-21BBD4C25DC7

P433

Q33893627-7814BE5C-60AA-434A-89E3-9EAAA8356B52

P478

Q33893627-6999CFB3-3382-41AF-AAB5-7398735344F2

P50

Q33893627-F7FED029-2585-42EC-909A-5075035947A7

P577

Q33893627-5E74F9FF-12E5-4128-887C-989ABE744223

P5875

Q33893627-E7ABA192-C0D0-4DE3-A463-E8F6402BA9AA

P698

Q33893627-FABAE44B-F303-40D8-A84A-07558A6A5796

P932

Q33893627-7BF395CC-E95F-4A3F-9845-638407F9FB4E

P356

P1433

Annals of Family Medicine

P1476

Use of acid-suppressive drugs ...... lysis of observational studies

@en

P2093

Chun-Sick Eom

http://www.w3.org/2001/XMLSchema#string

Jae Moon Yun

http://www.w3.org/2001/XMLSchema#string

Jeong-Soo Ahn

http://www.w3.org/2001/XMLSchema#string

Sang Min Park

http://www.w3.org/2001/XMLSchema#string

P2860

Quantifying heterogeneity in a meta-analysis

Meta-analysis in clinical trials

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

Helicobacter pylori.

Use of oral corticosteroids and risk of fractures.

Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.

Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans.

Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative

Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study

Long-term proton pump inhibitor therapy and risk of hip fracture.

P304

257-267

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1370/AFM.1243

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Seung-Kwon Myung

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51110951

http://www.w3.org/2001/XMLSchema#string

P698

21555754

http://www.w3.org/2001/XMLSchema#string

P932

3090435

http://www.w3.org/2001/XMLSchema#string